<DOC>
	<DOCNO>NCT02023333</DOCNO>
	<brief_summary>The purpose study evaluate good bad effect regorafenib use instead standard combination chemotherapy . It know take regorafenib versus standard chemotherapy well , bad result .</brief_summary>
	<brief_title>Regorafenib Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Age ≥ 18 year . Life expectancy least 12 week ( 3 month ) . Untreated metastatic colorectal cancer , progression first line 5FU contain regimen ( FOLFOX FOLFIRI ) Histologically proven colorectal adenocarcinoma Metastatic disease , unresectable disease involve one sit include liver , lung , lymph node peritoneum , nodule measure ≤3cm OR two site disease ( two nodule ) &gt; 4.5 cm . ECOG 0 1 Adequate bone marrow , liver liver function assess follow laboratory requirement : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 xULN ( ≤ 5 x ULN subject liver involvement cancer ) Alkaline phosphastase limit ≤ 2.5 x ULN ( ≤ 5 x ULN subject liver involvement cancer ) Lipase ≤ 1.5 x ULN Creatinine ≤ 1.5 x ULN Platelet count ≥ 100000 /mm3 hemoglobin ( Hb ) ≥ 9 g/dL , absolute neutrophil count ( ANC ) ≥ 1500/mm3 . Blood transfusion meet inclusion criterion allow . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start study drug . Postmenopausal woman ( defined menses least 1 year ) surgically sterilize woman require undergo pregnancy test . Subjects ( men woman ) childbearing potential must agree use adequate contraception begin sign ICF least 3 month last dose study drug . The definition adequate contraception base judgment site principal investigator designate associate . Subject must able swallow retain oral medication . If patient enrol MSK he/she must consent pre post treatment biopsy ( archived tissue available pretreatment analysis ) . Pretreatment archival tissue patient enrol outside MSK submit MSK . If archival tissue available , repeat biopsy require nonMSK patient . Uncontrolled hypertension ( systolic pressure &gt; 140 mm Hg diastolic pressure &gt; 90 mm Hg [ NCICTCAE v4.0 ] repeat measurement ) despite optimal medical management . Active clinically significant cardiac disease include : Congestive heart failure New York Heart Association ( NYHA ) &gt; Class II . Active coronary artery disease . Cardiac arrhythmia require antiarrhythmic therapy beta blocker digoxin . Unstable angina ( anginal symptom rest ) , newonset angina within 3 month randomization , myocardial infarction within 6 month randomization . Evidence history bleed diathesis coagulopathy . Any hemorrhage bleeding event ≥ NCI CTCAE Grade 3 within 4 week prior start study medication . Subjects previously untreated concurrent cancer distinct primary site Recent history prior cancer except cervical cancer situ , treat basal cell carcinoma , superficial bladder tumor . Subjects survive cancer curatively treat without evidence disease 3 year enrollment allow . Known history human immunodeficiency virus ( HIV ) infection current chronic active hepatitis B C infection require treatment antiviral therapy . Ongoing infection &gt; Grade 2 NCICTCAE v4.0 . Symptomatic metastatic brain meningeal tumor . Presence nonhealing wound , nonhealing ulcer , bone fracture . Patients seizure disorder require medication . Interstitial lung disease ongoing sign symptoms time informed consent . Pleural effusion ascites cause respiratory compromise ( ≥ NCICTCAE version 4.0 Grade 2 dyspnea ) . History organ allograft ( include corneal transplant ) . Any malabsorption condition . Women pregnant breastfeeding . Any condition , investigator 's opinion , make subject unsuitable trial participation . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Performance Status</keyword>
	<keyword>13-211</keyword>
</DOC>